Benefits of and Barriers to Pharmacogenomics-Guided Treatment for Major Depressive Disorder

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

Antidepressants have reduced the symptom burden for many Major Depressive Disorder (MDD) patients, but drug-related side effects and treatment resistance continue to present major challenges. Pharmacogenomics represents one approach to enhance antidepressant efficacy and avoid adverse reactions, but concerns remain with regard to the overall "value equation," and several barriers must be overcome to achieve the full potential of MDD pharmacogenomics.

Original languageEnglish (US)
JournalClinical Pharmacology and Therapeutics
DOIs
StateAccepted/In press - Jan 1 2018

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Benefits of and Barriers to Pharmacogenomics-Guided Treatment for Major Depressive Disorder'. Together they form a unique fingerprint.

  • Cite this